Literature DB >> 17379603

HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.

Sandra Rebouissou1, Sandrine Imbeaud, Charles Balabaud, Virginie Boulanger, Justine Bertrand-Michel, François Tercé, Charles Auffray, Paulette Bioulac-Sage, Jessica Zucman-Rossi.   

Abstract

Biallelic inactivating mutations of the transcription factor 1 gene (TCF1), encoding hepatocyte nuclear factor 1alpha (HNF1alpha) were identified in 50% of hepatocellular adenomas (HCA) phenotypically characterized by a striking steatosis. To understand the molecular basis of this aberrant lipid storage, we performed a microarray transcriptome analysis validated by quantitative reverse transcription-PCR, Western blotting, and lipid profiling. In mutated HCA, we showed a repression of gluconeogenesis coordinated with an activation of glycolysis, citrate shuttle, and fatty acid synthesis predicting elevated rates of lipogenesis. Moreover, the strong down-regulation of liver fatty acid-binding protein suggests that impaired fatty acid trafficking may also contribute to the fatty phenotype. In addition, transcriptional profile analysis of the observed deregulated genes in non-HNF1alpha-mutated HCA as well as in non-tumor livers allowed us to define a specific signature of the HNF1alpha-mutated HCA. In these tumors, lipid composition was dramatically modified according to the transcriptional deregulations identified in the fatty acid synthetic pathway. Surprisingly, lipogenesis activation did not operate through sterol regulatory element-binding protein-1 (SREBP-1) and carbohydrate-response element-binding protein (ChREBP) that were repressed. We conclude that steatosis in HNF1alpha-mutated HCA results mainly from an aberrant promotion of lipogenesis that is linked to HNF1alpha inactivation and that is independent of both SREBP-1 and ChREBP activation. Finally, our findings have potential clinical implications since lipogenesis can be efficiently inhibited by targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379603     DOI: 10.1074/jbc.M610725200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Hepatocellular adenoma management: advances but still a long way to go.

Authors:  Jean Frédéric Blanc; Nora Frulio; Laurence Chiche; Paulette Bioulac-Sage; Charles Balabaud
Journal:  Hepat Oncol       Date:  2015-05-15

Review 2.  Management of hepatic adenomatosis.

Authors:  Manish Thapar; Oleg Grapp; Constantine Fisher
Journal:  Curr Gastroenterol Rep       Date:  2015-03

3.  Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.

Authors:  Rondell P Graham; Luigi M Terracciano; Alexander Meves; Patrick M Vanderboom; Surendra Dasari; Matthew M Yeh; Michael S Torbenson; Michael W Cruise
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

4.  Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA.

Authors:  Jaclyn F Hechtman; Ghassan K Abou-Alfa; Zsofia K Stadler; Diana L Mandelker; Michael H A Roehrl; Ahmet Zehir; Efsevia Vakiani; Sumit Middha; David S Klimstra; Jinru Shia
Journal:  Hum Pathol       Date:  2018-08-17       Impact factor: 3.466

5.  Hepatocyte nuclear factor 1α-inactivated hepatocellular adenomas exhibit high (18)F-fludeoxyglucose uptake associated with glucose-6-phosphate transporter inactivation.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Osamu Matsui; Satoshi Saitoh; Yoshito Tomimaru; Takeshi Fujii; Toshifumi Gabata
Journal:  Br J Radiol       Date:  2016-05-20       Impact factor: 3.039

6.  Hepatocellular adenoma: what is new in 2008.

Authors:  Paulette Bioulac-Sage; Hervé Laumonier; Christophe Laurent; Jessica Zucman-Rossi; Charles Balabaud
Journal:  Hepatol Int       Date:  2008-05-01       Impact factor: 6.047

7.  Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage.

Authors:  Emmanuelle Jeannot; Lucille Mellottee; Paulette Bioulac-Sage; Charles Balabaud; Jean-Yves Scoazec; Jeanne Tran Van Nhieu; Yannick Bacq; Sophie Michalak; David Buob; Pierre Laurent-Puig; Ivan Rusyn; Jessica Zucman-Rossi
Journal:  Diabetes       Date:  2010-04-14       Impact factor: 9.461

8.  SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions.

Authors:  Yun Shin Chun; Michael G House; Harmeet Kaur; Evelyne M Loyer; Valérie Paradis; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2013-02-02       Impact factor: 3.452

9.  Expression of liver fatty acid binding protein in hepatocellular carcinoma.

Authors:  Soo-Jin Cho; Linda D Ferrell; Ryan M Gill
Journal:  Hum Pathol       Date:  2015-12-18       Impact factor: 3.466

Review 10.  Role of Wnt/β-catenin signaling in liver metabolism and cancer.

Authors:  Satdarshan Pal Singh Monga
Journal:  Int J Biochem Cell Biol       Date:  2009-09-09       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.